Product Information
DEXTROAMPH-AMPHET ER 12.5 MG CP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $8.2652 per EA under NDC 00480368301. Its NADAC has been published 118 times since May 22, 2024.
FDA first approved this application on Jan 31, 2022. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
DEXTROAMPH-AMPHET ER 12.5 MG CP
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfateStrength
3.125; 3.125; 3.125; 3.125 mg/1; mg/1; mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480368301
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA210876FDA Approved
1/31/2022
TE Code
AB2
On Market Since
10/10/2023
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMPH-AMPHET ER 12.5 MG CP has been published 118 times since May 22, 2024, and over the history we have for it it has risen 5.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.2652 per EA |
|---|---|
| All-time high | $8.8437 (Aug 13, 2025) |
| All-time low | $7.8649 (May 22, 2024) |
| 52-week high | $8.7921 |
| 52-week low | $8.0653 |
| Median price | $8.3525 |
| Average price | $8.3670 |
| Largest weekly change | +6.2% (Jun 19, 2024) |
| Weeks tracked | 118 |
| Tracking since | May 22, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DEXTROAMPH-AMPHET ER 12.5 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMPH-AMPHET ER 12.5 MG CP, manufactured by Teva Pharmaceuticals USA Inc., is $8.2652 per EA (NDC 00480368301), effective Aug 19, 2026.
How has the price of DEXTROAMPH-AMPHET ER 12.5 MG CP changed over time?
Over the history we have for it, the NADAC for DEXTROAMPH-AMPHET ER 12.5 MG CP has risen 5.1%. It has been tracked across 118 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for DEXTROAMPH-AMPHET ER 12.5 MG CP?
Since May 22, 2024, the NADAC for DEXTROAMPH-AMPHET ER 12.5 MG CP has ranged from a low of $7.8649 (May 22, 2024) to a high of $8.8437 (Aug 13, 2025), with a median of $8.3525 per EA.
Are there cheaper alternatives to DEXTROAMPH-AMPHET ER 12.5 MG CP?
No other NADAC-published product currently shares the active ingredient and strength of DEXTROAMPH-AMPHET ER 12.5 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMPH-AMPHET ER 12.5 MG CP?
DEXTROAMPH-AMPHET ER 12.5 MG CP (NDC 00480368301) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.